C3 glomerulopathy and current dilemmas

被引:25
作者
Ito, Naoko [1 ]
Ohashi, Ryuji [2 ]
Nagata, Michio [1 ]
机构
[1] Univ Tsukuba, Kidney & Vasc Pathol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan
[2] Nippon Med Coll Hosp, Dept Diagnost Pathol, Bunkyo Ku, 1-1-5 Sendagi, Tokyo 1138603, Japan
关键词
C3; glomerulopathy; Dense deposit disease; glomerulonephritis; Membranoproliferative glomerulonephritis; Alternative complement pathway; Dominant C3 deposition; DENSE DEPOSIT DISEASE; GLOMERULONEPHRITIS TYPE-II; ACUTE POSTINFECTIOUS GLOMERULONEPHRITIS; COMPLEMENT FACTOR-H; POSTSTREPTOCOCCAL ACUTE GLOMERULONEPHRITIS; HEMOLYTIC-UREMIC SYNDROME; LONG-TERM PROGNOSIS; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PROLIFERATIVE GLOMERULONEPHRITIS; MONOCLONAL GAMMOPATHY;
D O I
10.1007/s10157-016-1358-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
C3 glomerulopathy (C3G) is a recently identified disease entity caused by dysregulation of the alternative complement pathway, and dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) are its components. Because laboratory detection of complement dysregulation is still uncommon in practice, "dominant C3 deposition by two orders greater than that of immunoglobulins in the glomeruli by immunofluorescence", as stated in the consensus report, defines C3G. However, this morphological definition possibly includes the cases with glomerular diseases of different mechanisms such as post-infectious glomerulonephritis. In addition, the differential diagnosis between DDD and C3GN is often difficult because the distinction between these two diseases is based solely on electron microscopic features. Recent molecular and genetic advances provide information to characterize C3G. Some C3G cases are found with genetic abnormalities in complement regulatory factors, but majority of cases seem to be associated with acquired factors that dysregulate the alternative complement pathway. Because clinical courses and prognoses among glomerular diseases with dominant C3 deposition differ, further understanding the background mechanism, particularly complement dysregulation in C3G, is needed. This may resolve current dilemmas in practice and shed light on novel targeted therapies to remedy the dysregulated alternative complement pathway in C3G.
引用
收藏
页码:541 / 551
页数:11
相关论文
共 88 条
  • [1] Early recurrence of dense deposit disease with marked endocapillary proliferation after renal transplantation
    Aita, K
    Ito, S
    Tanabe, K
    Toma, H
    Yamaguchi, Y
    Nagata, M
    [J]. PATHOLOGY INTERNATIONAL, 2006, 56 (02) : 101 - 109
  • [2] BASEMENT-MEMBRANE CHANGES IN MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS .2. CHARACTERIZATION OF A 3RD TYPE BY SILVER IMPREGNATION OF ULTRA THIN-SECTIONS
    ANDERS, D
    AGRICOLA, B
    SIPPEL, M
    THOENES, W
    [J]. VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1977, 376 (01) : 1 - 19
  • [3] Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome
    Andresdottir, MB
    Assmann, KJM
    Hoitsma, AJ
    Koene, RAP
    Wetzels, JFM
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (07) : 1723 - 1731
  • [4] Diagnosis of complement alternative pathway disorders
    Angioi, Andrea
    Fervenza, Fernando C.
    Sethi, Sanjeev
    Zhang, Yuzhou
    Smith, Richard J.
    Murray, David
    Van Praet, Jens
    Pani, Antonello
    De Vriese, An S.
    [J]. KIDNEY INTERNATIONAL, 2016, 89 (02) : 278 - 288
  • [5] Membranoproliferative glomerulonephritis type II (dense deposit disease):: An update
    Appel, GB
    Cook, HT
    Hageman, G
    Jennette, JC
    Kashgarian, M
    Kirschfink, M
    Lambris, JD
    Lanning, L
    Lutz, HU
    Meri, S
    Rose, NR
    Salant, DJ
    Sethi, S
    Smith, RJH
    Smoyer, W
    Tully, HF
    Tully, SP
    Walker, P
    Welsh, M
    Würzner, R
    Zipfel, PF
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (05): : 1392 - 1403
  • [6] Familial C3 Glomerulopathy Associated with CFHR5 Mutations: Clinical Characteristics of 91 Patients in 16 Pedigrees
    Athanasiou, Yiannis
    Voskarides, Konstantinos
    Gale, Daniel P.
    Damianou, Loukas
    Patsias, Charalambos
    Zavros, Michalis
    Maxwell, Patrick H.
    Cook, H. Terence
    Demosthenous, Panayiota
    Hadjisavvas, Andreas
    Kyriacou, Kyriacos
    Zouvani, Ioanna
    Pierides, Alkis
    Deltas, Constantinos
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2011, 6 (06): : 1436 - 1446
  • [7] Update on C3 glomerulopathy
    Barbour, Thomas D.
    Ruseva, Marieta M.
    Pickering, Matthew C.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (05) : 717 - 725
  • [8] Dense Deposit Disease and C3 Glomerulopathy
    Barbour, Thomas D.
    Pickering, Matthew C.
    Cook, H. Terence
    [J]. SEMINARS IN NEPHROLOGY, 2013, 33 (06) : 493 - 507
  • [9] BERGER J, 1963, PRESSE MED, V71, P2351
  • [10] Pathogenesis of the C3 glomerulopathies and reclassification of MPGN
    Bomback, Andrew S.
    Appel, Gerald B.
    [J]. NATURE REVIEWS NEPHROLOGY, 2012, 8 (11) : 634 - 642